Daniel Lynch Net Worth & Insider Trades
Daniel Lynch - Director, Blueprint Medicines Corp
What is Daniel Lynch's Net Worth?
The current estimated net worth of Blueprint Medicines Corp's Director, Daniel Lynch, is estimated to be about $28.39M . Daniel Lynch owns about 174,342 units of Blueprint Medicines Corp common stock. In the last 5 years at Blueprint Medicines Corp, Daniel Lynch has sold an estimated value of $5.84M worth.
What is Daniel Lynch's Past Insider Trading?
Daniel Lynch's largest sale order was 32,500 units , worth over $1.63M on June 30, 2017. In total, Daniel Lynch has made about 18 transactions over 5 years of their time at Blueprint Medicines Corp. Daniel Lynch usually trades in June, with the busiest year in 2017. The most recent transaction was a sale order of 12,500 units , worth over $1.01M on February 16, 2018.
DANIEL LYNCH
Date Range: All Time
Ticker
|
Type
|
Value
|
Price per Share
|
Shares
|
Filing Date
| ||
|---|---|---|---|---|---|---|---|
| No matching records found | |||||||
Blueprint Medicines Corp Executive Compensation
Name |
Year
|
Salary
|
Total
|
|---|---|---|---|
| Jeffrey W. Albers | 2020 | $645,000 | $6,344,667 |
| Jeffrey W. Albers | 2019 | $590,000 | $9,362,371 |
| Jeffrey W. Albers | 2018 | $541,144 | $9,740,799 |
| Michael Landsittel | 2020 | $379,575 | $2,014,974 |
| Michael Landsittel | 2019 | $345,000 | $1,958,720 |
| Michael Landsittel | 2018 | $281,678 | $1,740,610 |
| Fouad Namouni, M.D. | 2020 | $186,154 | $6,668,732 |
| Fouad Namouni, M.D. | 2019 | - | - |
| Fouad Namouni, M.D. | 2018 | - | - |
| Kathryn Haviland | 2020 | $460,944 | $2,363,556 |
| Kathryn Haviland | 2019 | $431,830 | $3,090,423 |
| Kathryn Haviland | 2018 | $392,589 | $2,601,762 |
| Tracey L. McCain, Esq. | 2020 | $453,301 | $2,346,428 |
| Tracey L. McCain, Esq. | 2019 | $437,972 | $2,900,568 |
| Tracey L. McCain, Esq. | 2018 | $425,216 | $2,647,962 |
| No matching records found | |||
Source: https://www.sec.gov/Archives/edgar/data/1597264/000155837021004557/tmb-20210602xdef14a.htm
What are Blueprint Medicines Corp's Past Insider Trades?
Blueprint Medicines Corp's most recent insider trade came on March 8, 2023 by Christopher Murray who sold 1,875 units worth $85.64K . In the last 8 years, insiders at Blueprint Medicines Corp have sold an estimated value of $175.48M and bought an estimated value of $17.63M worth of shares. Insider trading is most common in March, with the busiest year in 2020. The most active traders at the company are Jeffrey Albers, Kate Haviland, CHIEF EXECUTIVE OFFICER, and Ariel Hurley, PRINCIPAL ACCOUNTING OFFICER .
Blueprint Medicines Corp Insider Trades
Date Range: All Time
Insider Names
|
Type
|
Value
|
Price per Share
|
Shares
|
Filing Date
| ||
|---|---|---|---|---|---|---|---|
| No matching records found | |||||||